Tung-Bo Chao1,2, Chien-Feng Li3,4,5,6, Ching-Yih Lin7,8, Yu-Feng Tian9,10, I-Wei Chang11, Ming-Jen Sheu7, Ying-En Lee12, Ti-Chun Chan3, Hong-Lin He11,13. 1. Department of Colorectal Surgery, Yuan's General Hospital, Kaohsiung, Taiwan. 2. Department of Health Business Administration, Meiho University, Pingtung, Taiwan. 3. Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan. 4. National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. 5. Department of Biotechnology, Southern Taiwan University of Science & Technology, Tainan, Taiwan. 6. Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 7. Division of Gastroenterology & Hepatology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan. 8. Department of Leisure, Recreation, & Tourism Management, Southern Taiwan University of Science & Technology, Tainan, Taiwan. 9. Division of General Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan. 10. Department of Health & Nutrition, Chia Nan University of Pharmacy & Science, Tainan, Taiwan. 11. Department of Pathology, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan. 12. Department of Anesthesiology, Kaohsiung Chang Gung Memorial Hospital & Chang Gung University College of Medicine, Kaohsiung, Taiwan. 13. Institute of Biomedical Science, National Sun Yat-Sen University, Kaohsiung, Taiwan.
Abstract
AIM: This study aimed to investigate the prognostic significance of DSG3 and its association with response to neoadjuvant concurrent chemoradiotherapy (CCRT) in rectal cancer. MATERIALS & METHODS: Data mining of a publicly available dataset was performed to find genes associated with CCRT response. Immunohistochemistry was applied to evaluate DSG3 expression. The relationships between DSG3 expression and various clinicopathological parameters and survival were analyzed. RESULTS: The DSG3 gene was significantly associated with CCRT response. The expression of DSG3 negatively correlated with poorer tumor regression (p < 0.001) and had an independent negative impact on disease-specific survival (p = 0.011), local recurrence-free survival (p = 0.031) and metastasis-free survival (p = 0.029). CONCLUSION: DSG3 was a key prognostic factor and predictor for CCRT response in rectal cancer patients.
AIM: This study aimed to investigate the prognostic significance of DSG3 and its association with response to neoadjuvant concurrent chemoradiotherapy (CCRT) in rectal cancer. MATERIALS & METHODS: Data mining of a publicly available dataset was performed to find genes associated with CCRT response. Immunohistochemistry was applied to evaluate DSG3 expression. The relationships between DSG3 expression and various clinicopathological parameters and survival were analyzed. RESULTS: The DSG3 gene was significantly associated with CCRT response. The expression of DSG3 negatively correlated with poorer tumor regression (p < 0.001) and had an independent negative impact on disease-specific survival (p = 0.011), local recurrence-free survival (p = 0.031) and metastasis-free survival (p = 0.029). CONCLUSION:DSG3 was a key prognostic factor and predictor for CCRT response in rectal cancerpatients.